About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPARE-II- Vasomotion and Imaging Substudy | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 4NCT01329237

COMPARE-II- Vasomotion and Imaging Substudy

The purpose of the study is to compare strut coverage and neointimal thickness between everolimus eluting (XIENCE-V® or PROMUS® stent) and biolimus A9 eluting NOBORI Stent 14 months after stent implan...

Lead sponsor: University of Freiburg•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Mario Togni, MD

CONTACT

++41-26-426-8130 [email protected]

Stéphane Cook, MD

CONTACT

++41-26-426-8130 [email protected]

Sponsors

Lead Sponsor

University of Freiburg

DESIGN: Imaging and vasomotion Substudy: 50 consecutive patients enrolled in the COMPARE II trial at the University of Fribourg Medical Center will undergo follow-up re-angiography 14 months after index procedure with assessment of Optical coherence tomography (OCT) and vasomotion testing. ENDPOINT SUBSTUDY (all at 14 months): Primary endpoint imaging: percentage of uncovered stent struts per lesion and mean neointimal thickness assessed by OCT. vasomotion: coronary vasomotion assessed with quantitative coronary angiography at rest and during supine bicycle exercise.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patient enrolled in the COMPARE II trial with successful stent implantation and absence of binary restenosis or severe progression of coronary artery disease at 14 months follow-up.
•Patient consent to undergo a non-scheduled follow- up angiography with imaging study and bicycle exercise testing

Exclusion Criteria

•1. Inability to provide informed consent
•2. Inability to perform a supine bicycle exercise stress test
•3. Binary in stent restenosis of the target vessel
•4. Acute Coronary Syndrome, Acute Myocardial Infarction
•5. Patients with stent thrombosis following the index procedure
•6. Female of childbearing potential ( age ≤ 50 years and last menstruation within the last 12 months ), who did not undergo tubal ligation, ovariectomy or hysterectomy
•7. Known intolerance to heparin, contrast material
•8. History of bleeding diathesis or known coagulopathy
•9. Age ≥ 80 years
•10. Hemodynamic instability
•11. Renal failure (creatinine clearance ≤ 40 ml/min)
•12. OCT / IVUS technically not feasible

Related studies

Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque

NCT07660419 · Coronary Artery Disease (CAD), Coronary Stenosis

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630 · Coronary Artery Disease

Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry

NCT07565805 · Coronary Artery Disease (CAD)

RECRUITINGPhase 2

Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

NCT07560436 · Heart Failure With Preserved Ejection Fraction (HFPEF), Coronary Artery Disease

Strategic Comparison Of Ischemia-based Versus Plaque Burden and vulnErability-based Revascularization in High-Risk Coronary Artery Disease Patients

NCT07324720 · Coronary Artery Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 5, 2011Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment50

Start dateMar 2011

Last updatedApr 5, 2011

Condition

Coronary Artery Disease

Locations shown

Hopital Cantonal HFR

Fribourg, Canton of Fribourg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2011Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions